Paraneoplastic, Autoantibody Evaluation, Serum
Use
The Paraneoplastic Autoantibody Evaluation is aimed at identifying autoantibodies linked to neurological disorders associated with cancer. It is useful for investigating neurological symptoms in patients with a history of cancer treatment and can differentiate autoimmune neuropathies from neuropathies caused by chemotherapy. The test is valuable for detecting autoantibodies that may indicate cancer recurrence in previously seropositive patients, hence aiding a focused cancer search.
Special Instructions
This test should not be used for patients who have recently received radioisotopes. Specimens will be screened for radioactivity before analysis. Collection of specimens is advised prior to starting immunosuppressant or IVIg treatments.
Limitations
Negative results do not exclude cancer. There is potential interference from immunosuppressive treatments which may lead to false-negative results. This test does not encompass all known antibodies related to autoimmune neurological disorders and has a limited ability to predict the specific neurological syndrome.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 43104-9
- 84927-3
- 72327-0
- 33615-6
- 43187-4
- 43102-3
- 72504-4
- 57771-8
- 48767-8
- 84925-7
- 84924-0
- 84926-5
Result Turnaround Time
10-17 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
4 mL
Minimum Volume
2 mL
Container
Plastic vial; Preferred: Red top, Acceptable: Serum gel
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
For optimal antibody detection, specimen collection is recommended before starting immunosuppressant medication or IVIg treatment.
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |